bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Deutsche Bank 39 th Annual Health Care Conference on Thursday, May 8, 2014 at 8:00 AM( EDT) at the InterContinental Boston Hotel, Boston, Massachusetts. Management will also present at the Bank of America Healthcare Conference on Wednesday, May 14, 2014 at 3:40 PM (PDT) at the Encore at Wynn Hotel, Las Vegas, Nevada and at the UBS Global Healthcare Conference on Wednesday, May 21, 2014 at 11:00 AM (ET) at the Sheraton New York Hotel, New York, New York. To access a simultaneous webcast of these presentations via the internet, log on to the "Calendar of Events" section on the Investor and Media page of the bluebird bio website at http://investor.bluebirdbio.com. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast. A replay of the webcasts will be available on bluebird bio website for ninety days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Calendar of Events" section of the Investor and Media page of the bluebird bio's website at http://investor.bluebirdbio.com. About bluebird bio, Inc. bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases. bluebird bio has two clinical-stage programs in development. The most advanced product candidate, Lenti-D, is in a recently-initiated phase 2/3 study, the Starbeam Study, for the treatment of childhood cerebral adrenoleukodystrophy (CCALD), a rare, hereditary neurological disorder affecting young boys. The next most advanced product candidate, LentiGlobin, is currently in two phase 1/2 studies, one in the US (the Northstar Study) and one in France (HGB-205), for the treatment of beta-thalassemia major. The phase 1/2 HGB-205 study also allows enrollment of patient(s) with sickle cell disease, and bluebird bio is planning a separate U.S. sickle cell disease trial in which the first patient is expected to enroll in 2014.
bluebird bio also has an early-stage chimeric antigen receptor-modified T cell (CAR-T) program for oncology in partnership with Celgene Corporation.bluebird bio has operations in Cambridge, Massachusetts and Paris, France. For more information, please visit www.bluebirdbio.com Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the advancement of, and anticipated milestones related to the Company’s product candidates and clinical studies. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk of cessation or delay of any of the ongoing or planned clinical studies and/or our development of our product candidates, the risk of a delay in the enrollment of patients in the Company’s clinical studies, the risk that the results of previously conducted studies involving similar product candidates will not be repeated or observed in ongoing or future studies involving current product candidates, the risk that our collaboration with Celgene will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law. Availability of other information about bluebird bio Investors and others should note that we communicate with our investors and the public using our company website ( www.bluebirdbio.com ), our investor relations website ( http://www.bluebirdbio.com/investor-splash.html ), including but not limited to investor presentations and FAQs,Securities and Exchange Commission filings, press releases, public conference calls and webcasts. You can also connect with us on Twitter @bluebirdbio or LinkedIn . The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in bluebird bio to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include other social media channels than the ones described above. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.